CLINICAL_TRIALS
trial_result
· 2021-08-20
Clinical Trial Update: An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis [Phase 2]
Summary
Phase 2 trial results for an oral p38 inhibitor in active rheumatoid arthritis assessing safety, efficacy, and pharmacokinetics.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Arthritis, Rheumatoid | Phase 2 | Status: COMPLETED | Results posted: 2021-08-20